BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 30237798)

  • 1. Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma.
    van Dinther D; Veninga H; Revet M; Hoogterp L; Olesek K; Grabowska J; Borg EGF; Kalay H; van Kooyk Y; den Haan JMM
    Front Immunol; 2018; 9():1997. PubMed ID: 30237798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD169
    Grabowska J; Lopez-Venegas MA; Affandi AJ; den Haan JMM
    Front Immunol; 2018; 9():2472. PubMed ID: 30416504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible functions of CD169-positive sinus macrophages in lymph nodes in anti-tumor immune responses.
    Komohara Y; Ohnishi K; Takeya M
    Cancer Sci; 2017 Mar; 108(3):290-295. PubMed ID: 28002629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional CD169 on Macrophages Mediates Interaction with Dendritic Cells for CD8
    van Dinther D; Veninga H; Iborra S; Borg EGF; Hoogterp L; Olesek K; Beijer MR; Schetters STT; Kalay H; Garcia-Vallejo JJ; Franken KL; Cham LB; Lang KS; van Kooyk Y; Sancho D; Crocker PR; den Haan JMM
    Cell Rep; 2018 Feb; 22(6):1484-1495. PubMed ID: 29425504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective tumor antigen vaccine delivery to human CD169
    Affandi AJ; Grabowska J; Olesek K; Lopez Venegas M; Barbaria A; Rodríguez E; Mulder PPG; Pijffers HJ; Ambrosini M; Kalay H; O'Toole T; Zwart ES; Kazemier G; Nazmi K; Bikker FJ; Stöckl J; van den Eertwegh AJM; de Gruijl TD; Storm G; van Kooyk Y; den Haan JMM
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27528-27539. PubMed ID: 33067394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD169 mediates the capture of exosomes in spleen and lymph node.
    Saunderson SC; Dunn AC; Crocker PR; McLellan AD
    Blood; 2014 Jan; 123(2):208-16. PubMed ID: 24255917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of CD169+ Lymph Node Sinus Macrophages in Patients with Malignant Melanoma.
    Saito Y; Ohnishi K; Miyashita A; Nakahara S; Fujiwara Y; Horlad H; Motoshima T; Fukushima S; Jinnin M; Ihn H; Takeya M; Komohara Y
    Cancer Immunol Res; 2015 Dec; 3(12):1356-63. PubMed ID: 26297710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted delivery of lipid antigen to macrophages via the CD169/sialoadhesin endocytic pathway induces robust invariant natural killer T cell activation.
    Kawasaki N; Vela JL; Nycholat CM; Rademacher C; Khurana A; van Rooijen N; Crocker PR; Kronenberg M; Paulson JC
    Proc Natl Acad Sci U S A; 2013 May; 110(19):7826-31. PubMed ID: 23610394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD169+ Subcapsular Macrophage Role in Antigen Adjuvant Activity.
    Lisk C; Yuen R; Kuniholm J; Antos D; Reiser ML; Wetzler LM
    Front Immunol; 2021; 12():624197. PubMed ID: 33815376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.
    Kranz LM; Diken M; Haas H; Kreiter S; Loquai C; Reuter KC; Meng M; Fritz D; Vascotto F; Hefesha H; Grunwitz C; Vormehr M; Hüsemann Y; Selmi A; Kuhn AN; Buck J; Derhovanessian E; Rae R; Attig S; Diekmann J; Jabulowsky RA; Heesch S; Hassel J; Langguth P; Grabbe S; Huber C; Türeci Ö; Sahin U
    Nature; 2016 Jun; 534(7607):396-401. PubMed ID: 27281205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of CD8⁺ T Cell Responses after Melanoma Antigen Targeting to CD169⁺ Antigen Presenting Cells in Mice and Humans.
    van Dinther D; Lopez Venegas M; Veninga H; Olesek K; Hoogterp L; Revet M; Ambrosini M; Kalay H; Stöckl J; van Kooyk Y; den Haan JMM
    Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30764534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients.
    Tuettenberg A; Becker C; Huter E; Knop J; Enk AH; Jonuleit H
    Int J Cancer; 2006 May; 118(10):2617-27. PubMed ID: 16353138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of viral peptide targeting to porcine sialoadhesin using a porcine reproductive and respiratory syndrome virus vaccination-challenge model.
    Ooms K; Van Gorp H; Botti S; Van Gaever T; Delputte PL; Nauwynck HJ
    Virus Res; 2013 Nov; 177(2):147-55. PubMed ID: 23932898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CD169 sialoadhesin molecule mediates cytotoxic T-cell responses to tumour apoptotic vesicles.
    Black LV; Saunderson SC; Coutinho FP; Muhsin-Sharafaldine MR; Damani TT; Dunn AC; McLellan AD
    Immunol Cell Biol; 2016 May; 94(5):430-8. PubMed ID: 26647968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
    Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
    J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
    Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
    Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Protective Role for the Lectin CD169/Siglec-1 against a Pathogenic Murine Retrovirus.
    Uchil PD; Pi R; Haugh KA; Ladinsky MS; Ventura JD; Barrett BS; Santiago ML; Bjorkman PJ; Kassiotis G; Sewald X; Mothes W
    Cell Host Microbe; 2019 Jan; 25(1):87-100.e10. PubMed ID: 30595553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic and functional heterogeneity of CD169⁺ and CD163⁺ macrophages from porcine lymph nodes and spleen.
    Alvarez B; Martínez P; Yuste M; Poderoso T; Alonso F; Domínguez J; Ezquerra A; Revilla C
    Dev Comp Immunol; 2014 May; 44(1):44-9. PubMed ID: 24291017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Delivery of Antigen to Activated CD169
    Edgar LJ; Kawasaki N; Nycholat CM; Paulson JC
    Cell Chem Biol; 2019 Jan; 26(1):131-136.e4. PubMed ID: 30393066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.